Project Grant K99HL181293
Award Date 8/15/26
Completion Date 7/31/28
Dollars Obligated $131K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Santa Barbara, CA 93106, USA
Similar Awards
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $231,552 Project Grant to the University of California, San Diego on September 16, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). This research project, titled "Tissue Elasticity and Viscosity Modulates Macrophage-Fibroblast Signaling in Cardiac Fibrosis," focuses on investigating the mechanisms underlying cardiac fibrosis through the study of interactions between...
- The National Heart, Lung, and Blood Institute awarded the University of California, Los Angeles $1.368 million on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanosensitive signaling mechanisms that support endothelial cell resilience in the context of cardiovascular disease treatment. The research elucidates a mechanosensitive signaling domain in endothelial cells and tests how TRPV4-mediated calcium signaling promotes vascular resilience....
- The National Heart, Lung, and Blood Institute awarded $609,574 to the University of California, San Diego on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research into the cellular and molecular mechanisms regulating cardiac chamber morphology. The recipient is investigating how cardiomyocytes acquire distinct shapes and organizational patterns in the outer and inner curvatures of the embryonic ventricle, which establish proper cardiac chamber...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $770,000 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research unraveling endothelial-cardiomyocyte crosstalk in cardiomyopathy using an integrated multimodal approach. The research examines molecular mechanisms by which endothelial dysfunction contributes to cardiac dysfunction in cardiomyopathy, focusing on cell-to-cell signaling between endothelial cells...
- The National Heart, Lung, and Blood Institute awarded the University of California, San Diego $1,601,981 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate protein aggregation mechanisms in hematopoietic stem cells and their relationship to stem cell aging. The research examines how hematopoietic stem cells traffic misfolded proteins to aggresomes—cytosolic inclusion bodies that are substrates for selective autophagy—and tests the hypothesis...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $768,830 on July 6, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate immune-fibroblast crosstalk in genetic dilated cardiomyopathy. The research integrates patient-specific induced pluripotent stem cells (iPSCs), three-dimensional cardiac organoids embedded in engineered disease-specific niches, CRISPR-based high-throughput screening, single-cell RNA sequencing,...
- The National Heart, Lung, and Blood Institute awarded the University of California, San Diego $779,600 on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the developmental mechanisms that direct cardiac cell diversification and left ventricle morphogenesis. The research employs single-cell transcriptomic analyses and lineage tracing in mouse embryos to define the gene regulatory networks controlling how diverse cardiac cell types emerge from...
- The National Heart, Lung, and Blood Institute awarded the University of Southern California $240,206 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 1, 2026, to engineer therapeutically programmed monocytes that adaptively immunomodulate the post-infarction myocardial microenvironment toward cardiac repair and regeneration. The award funds development of smart monocytes using synnotch receptor circuits that detect inflammation and respond by secreting...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $767,249 on June 22, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate computational models for designing organ-scale vasculature in biomanufactured cardiac tissues. The project addresses the need for patient-specific engineered tissues to repair complex congenital heart defects, particularly large ventricular septal defects where current surgical approaches...
- The National Heart, Lung, and Blood Institute awarded the University of California, Davis $590,503 on August 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on cardiac regenerative therapy using gene-edited stem cells to improve transplantation outcomes in end-stage heart failure. The research addresses inflammation-mediated cell death that impedes cardiac stem cell therapy by modifying both donor cells and the host environment to target genes...